- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00170456
Phase II Study of Range and Schedule of rPA Doses
A Double-Blind, Parallel-Group Study of the Safety, Tolerability and Immunogenicity of a Range of Doses and Dosing Schedules of Recombinant (rPA Based) Anthrax Vaccine in Healthy Subjects
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom
- GDRU, Quintiles Ltd
-
Merthyr Tydfil, United Kingdom, CF48 4DR
- Simbec Research Limited
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy males or females.
- Aged between 18-55 years (inclusive).
- A body mass index (BMI) of 18-35.
- Signed informed consent, which includes information about the potential risks and effects of rPA.
- A medical history without major organ pathology (e.g. cardiac, immunological, psychiatric, endocrine or neurological disorders, cancer or other wasting diseases - (adequately treated actinic keratosis, or basal cell carcinoma [BCC], or carcinoma in situ [CIS] of the cervix are permitted).
A female may be enrolled if one of the following criteria applies:
Either If of child-bearing capacity then: A female is not pregnant or breast feeding AND is routinely using adequate injectable or transdermal (administered at the recommended frequency) or oral contraception (at a stable dose for at least three months prior to the first dose of vaccine) and will continue to do so during the study, augmenting this contraceptive measure with a barrier method OR is sexually abstinent OR is monogamous and has a partner who has had a vasectomy (>1 month previously) OR is using a commonly recognised copper and hormone implanted intrauterine device (IUD) such as TCu-380A, TCu-220C, MLCu-375, Nova-T or LNG-20. In addition, the subject must have a negative blood pregnancy test prior to enrolment into the study and negative urine pregnancy test pre-dose.
Or A female is post menopausal (defined as a female with no menstrual cycle for at least 24 months and of menopausal age (>45 years).
Or A female with no menstrual cycle for between 12 and 24 months and of menopausal age (>45 years) who has a negative blood pregnancy test prior to enrolment into the study and a negative urine pregnancy test pre-dose.
Or A female has been surgically sterilised (confirmed by review of medical record).
Or A female has had a total hysterectomy at least 3 months prior to the start of the study (confirmed by review of medical record).
- A male may be enrolled if willing to use barrier methods of contraception and whose partner is using an acceptable form of contraception for 3 months post each dose.
- Able to understand the informed consent form and other documents required to be read by the subject.
Exclusion Criteria:
- Presence of any clinically significant medical condition as determined by the Investigator.
- Medically significant hypersensitivity or idiosyncratic reaction related to any medical product including vaccines.
- History or evidence of drug abuse.
- Participation in a clinical study of an investigational vaccine within 3 months prior to the start of the study or an investigational drug product within 30 days prior to the start of the study.
- Use of any prescription or non-prescription medication within 7 days prior to the first dosing with the exception of over-the-counter (OTC) antihistamine, non-steroidal anti-inflammatory drugs (NSAID), acetaminophen, OTC decongestants or oral/injectable/transdermal contraceptives. Any medication taken within 7 days of the first dosing will be recorded.
- History or suspicion of inability to co-operate adequately.
- Donation of blood or blood products for a period of 4 weeks prior to participation in the study.
- Immunodeficiency or clinically active autoimmune disease.
- Positive urine alcohol and drug screen for drugs of abuse (opiates, methadone, cocaine, amphetamines, cannabinoids, and barbiturates).
- Positive test for human immunodeficiency virus (HIV), and/or hepatitis B and/or hepatitis C.
- Vaccination(s) with a live vaccine in the previous 4 weeks or killed / inactivated vaccines in the previous 3 weeks.
- Blood or plasma transfusions, or pooled gamma-globulin in the previous 3 months and need for blood or plasma transfusions during this study.
- Received anthrax vaccine or anthrax immune globulin or been otherwise exposed to B. anthracis.
- Clinically relevant abnormal findings on routine physical examination.
- Clinically significant out-of-range laboratory tests at screening including: urinalysis, serum creatinine, lactate dehydrogenase (LDH), potassium, glucose, liver function tests (LFT); absolute neutrophil count, platelet count, white blood cell count, electrolytes, clotting and blood haemoglobin.
- Twelve-lead ECG recording with clinically relevant signs of pathology and conduction disturbances as judged by the investigator.
- Presence of tattoos that cover or partially cover the upper arm.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Low dose rPA vaccine regime 1
|
|
Active Comparator: 2
Low dose rPA vaccine regime 2
|
|
Active Comparator: 3
High dose rPA vaccine regime 1
|
|
Active Comparator: 4
High dose rPA vaccine regime 2
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Safety of rPA vaccine
|
Secondary Outcome Measures
Outcome Measure |
---|
Immunogenicity of rPA vaccine
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Timothy Mant, MD, GDRU, London, UK
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Bacillaceae Infections
- Anthrax
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Immunologic Factors
- Gastrointestinal Agents
- Adjuvants, Immunologic
- Antacids
- Aluminum Hydroxide
Other Study ID Numbers
- 05-0003
- QGUY/2004/AV-rPA/-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prevention of Bacillus Anthracis (Anthrax) Infection
-
Emergent BioSolutionsNational Institute of Allergy and Infectious Diseases (NIAID); Department of...CompletedBacillus Anthracis (Anthrax) InfectionUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedBacillus Anthracis (Anthrax)United States
-
National Institute of Allergy and Infectious Diseases...Terminated
-
PharmAthene UK LimitedNational Institute of Allergy and Infectious Diseases (NIAID)CompletedBacillus Anthracis (Anthrax)United States
-
National Institute of Allergy and Infectious Diseases...Completed
-
VaxGenCompletedTrial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen VaccinePrevention of Anthrax InfectionUnited States
-
TaiMed Biologics Inc.Bill and Melinda Gates Foundation; Aaron Diamond AIDS Research CenterCompletedPrevention of Infection With HIV-1United States
-
Klein, Jeffrey A., M.D.Completed
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Merck Sharp & Dohme LLCCompletedCancer Survivor | Prevention of Human Papillomavirus InfectionUnited States
-
Balgrist University HospitalIndustry (Schülke & Mayr AG, Switzerland and Germany)RecruitingElective Surgery | High Risk | Prevention of Surgical Site Infections | Randomized-controlled TrialSwitzerland
Clinical Trials on rPA vaccine containing alhydrogel
-
PharmAthene UK LimitedNational Institute of Allergy and Infectious Diseases (NIAID)CompletedBacillus Anthracis (Anthrax)United States
-
National Institute of Allergy and Infectious Diseases...Terminated
-
MedicagoHealth Sciences Centre, Winnipeg, Manitoba; Syneos Health; Public Health Agency...CompletedRNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract DiseasesCanada
-
MedicagoMcGill University Health Centre/Research Institute of the McGill University... and other collaboratorsCompletedImmunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract DiseasesCanada
-
Institut PasteurWellcome Trust; Walter Reed Army Institute of Research (WRAIR); Parexel; Bill &... and other collaboratorsActive, not recruiting
-
Centre Hospitalier Universitaire Saint PierreUniversité Libre de BruxellesNot yet recruitingPertussis | Maternal-Fetal Relations | Vaccination; Infection | ImmunoglobulinsBelgium
-
Universiteit AntwerpenChulalongkorn University; Thrasher Research Fund; Institut Pasteur de LilleCompleted
-
Baylor College of MedicineGeorge Washington University; Makerere University Walter Reed ProjectActive, not recruitingSchistosomiasis | Schistosoma MansoniUganda
-
Baylor College of MedicineCompletedHookworm Infection | Hookworm DiseaseBrazil
-
St George's, University of LondonThrasher Research Fund; Department of Health, United KingdomUnknownPertussis | Pregnancy Related | Immunization; InfectionUnited Kingdom